聚乙二醇化干扰素α-2b治疗真性红细胞增多症和原发性血小板增多症后对JAK2突变状态的影响有限。
Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
作者信息
Samuelsson Jan, Mutschler Manuel, Birgegård Gunnar, Gram-Hansen Poul, Björkholm Magnus, Pahl Heike L
出版信息
Haematologica. 2006 Sep;91(9):1281-2.
PMID:16956836
Abstract
Twenty-five patients with myeloproliferative diseases were treated with pegylated interferon alpha-2b. Prior to therapy, 15/25 patients had a JAK2(V617F) mutation. Eight JAK2-positive patients were on therapy in hematological complete remission at 24 months. Five of eight patients demonstrated a 1.2-3.6 fold reduction in the percentage of JAK2(V617F) cells.
摘要
25例骨髓增殖性疾病患者接受了聚乙二醇化干扰素α-2b治疗。治疗前，25例患者中有15例存在JAK2（V617F）突变。8例JAK2阳性患者在治疗24个月时达到血液学完全缓解。8例患者中有5例JAK2（V617F）细胞百分比降低了1.2至3.6倍。
Zotero 插件